CANCER-MED

Cancer is a leading cause of death worldwide, having reached epidemic proportions. Each year, millions of people are diagnosed with the disease, of which there are more than 100 types, and the effects on their health and quality of life can be devastating.
Despite significant progress in available treatments, cancer continues to be a major health problem globally. Both large- and small-cap companies are involved in developing new ways of diagnosing and treating the disease. With the costs of treating cancer on the rise, successful treatment programs can lead to increased revenues for these companies, which, in turn, can lead to higher share prices.
The process of selecting assets for the portfolio is as follows: first, stocks available on Bit Digital are scanned for companies involved in cancer treatment innovation. Cancer drug manufacturers, as well as companies involved in the diagnosis and research of the disease, are considered. Then, each stock undergoes a screening process based on a series of metrics, such as market capitalisation, liquidity of shares, financial ratios and analysts' consensus ratings. The metrics form the basis for the stocks’ rankings. Finally, the top-ranked stocks are included in the portfolio and weighted equally.

The portfolio will be rebalanced yearly or at Bit Digital’s discretion, pending market conditions.
Your capital is at risk.
This is a marketing communication and should not be taken as investment advice, personal recommendation, or an offer of, or solicitation to, buy or sell any financial instruments. This material has been prepared without taking any particular recipient’s investment objectives or financial situation into account, and has not been prepared in accordance with the legal and regulatory requirements to promote independent research. Any references to the past or future performance of a financial instrument, index or a packaged investment product are not, and should not be taken as, a reliable indicator of future results.